The synergistic effect of Dactolisib and Crizotinib in a triple-negative breast cancer model (Singh et al. 2022) reduced MAPK, PI3K/Akt, JAK/STAT pathway activity, and EMT markers. Here, AKT1 is linked to triple-negative breast carcinoma.